产品详细信息
- 安捷伦稳定性方案设计用于支持药品的全球注册。这些方案包括：
- 稳定性项目以支持 API 及最终药品
- 确认的药品稳定性试验箱用于所有的 ICH 条件，包括光稳定性
- GLP 研究及剂量配方分析
- 统计学分析及数据趋势分析
- 产品样本
-
Brochure - NASD - Delivering Solutions for Nucleic Acid Therapeutics
Nucleic Acid Solutions Division Overview Brochure.
- 产品样本
- English
- 2020 年 6 月 15 日
- 3.37 MB
- 宣传单页
Senior Director
Process chemistry
We like the collaborative nature of our partnership. Agilent works with us to truly understand our needs and how to best meet them, even when they change overtime.
查看更多Scientific Director
Analytical Development
Agilent provides program guidance and suggestions based on their extensive internal expertise, which helps avoid “re-inventing the wheel”.
查看更多视频
Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases. The addition of two new manufacturing lines (known as Trains C and D) will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.
- 2022 年 12 月 5 日